Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)

Goldman Sachs analyst Corinne Jenkins reiterated a Buy rating and $24.00 price target on Roivant Sciences (NASDAQ: ROIV)

The analyst comments: "On the back of Ph3 VALOR results in dermatomyositis, our investor conversations have primarily focused on what comes next for the stock; in our view, the key debate for ROIV post data has shifted to whether the company can become the next mid-cap growth story as it seeks to build a multi-product commercial franchise. To that end, we highlight multiple upcoming clinical catalysts in 2026-2027: i) four proof-of-concept read-outs in 2026, across IMVT-1402 (cutaneous lupus erythematosus, difficult-to-treat rheumatoid arthritis), brepocitinib (cutaneous sarcoidosis), and mosliciguat (pulmonary hypertension with interstitial lung disease); ii) multiple registrational program read-outs in 2027, including IMVT-1402 (Graves' disease, difficult-to-treat RA, and myasthenia gravis), brepocitinib (non-infectious uveitis), iii) the commercial launch of brepocitinib in 2027, iv) updates from ROIV on the ongoing litigation between its subsidiaries (Arbutus/Genevant) and MRNA/PFE/BNTX related to patent infringement for the COVID-19 vaccines, and v) any potential business development from here. Given the robust calendar across both proof-of-concept programs where we see meaningful potential discovery value and registrational read-outs which could support additional multi-blockbuster commercial launches, we view the recent data as just the start of a multi-year transformational period for ROIV which should translate to meaningful share outperformance with de-risking events for a cumulative >$10B in peak sales (~$15/share; >60% vs. our 12-month price target of $24) over the next two years (per GS estimates)."

For an analyst ratings summary and ratings history on Roivant Sciences click here. For more ratings news on Roivant Sciences click here.

Shares of Roivant Sciences closed at $15.10 yesterday.

You May Also Be Interested In

• Goldman Sachs Reinstates Etsy (ETSY) at Neutral
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight